KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

Purpose: Type 1 diabetes mellitus (T1DM), as an autoimmune disease, can increase susceptibility to clear cell renal cell carcinoma (ccRCC ... of the hub genes were confirmed via RT-qPCR and IHC, and ...

Standard pathological assessment also includes immunohistochemistry ... of adrenocortical carcinoma. 69,112–114 There is increasing evidence that there are probably three molecular subtypes bearing ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

What Is Renal Cell Carcinoma? It's the most common type of kidney cancer. Although it’s a serious disease, finding and treating it early makes it more likely that you’ll be cured. No matter ...

Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study. Mortality risk in clinical T1a renal cell ...

Get Instant Summarized Text (Gist) The CLEAR study highlights the importance of tumor size reduction in enhancing survival outcomes for advanced renal cell carcinoma (aRCC) patients. The ...

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.